Treatments in Phase 3 Trials

Biologics

Name: BCD-057
Indication: Psoriasis

  • BIOCAD
  • Biosimilar for Humira (adalimumab)
  • TNF-alpha inhibitor

Name: BCD-085
Indication: Psoriasis and PsA

  • BIOCAD
  • IL-17 inhibitor

Name: BI695501
Indication: Psoriasis

  • Boehreinger Ingelheim
  • Biosimilar for Humira (adalimumab)
  • TNF-alpha inhibitor

Name: Bimekizumab (UCB4940)
Indication: Psoriasis and PsA

  • UCB
  • IL-17A and IL-17F inhibitor

Name: CHS-1420
Indication: Psoriasis

  • Coherus Biosciences
  • Biosimilar for Humira (adalimumab)
  • TNF-alpha inhibitor

Name: GP2017
Indication: Psoriasis

  • Sandoz
  • Biosimilar for Humira (adalimumab)
  • TNF-alpha inhibitor

Name: Mirikizumab (LY3074828)
Indication: Psoriasis

  • Eli Lilly
  • IL-23 inhibitor

Name: PF-06438179
Indication: Psoriasis

  • Pfizer
  • Biosimilar for Remicade (infliximab)
  • TNF-alpha inhibitor

Oral Treatments

Name: BMS-986165 (deucravacitinib)
Indication: Psoriasis and PsA

  • Bristol-Myers Squibb
  • TYK2 kinase inhibitor


Name: CF101 (piclidenoson)
Indication: Psoriasis

  • Can-Fite BioPharma
  • Adenosine A3 receptor inhibitor


Name: Filgotinib (GLPG0634)
Indication: PsA

  • Galapagnos NV
  • JAK1 inhibitor


Name: LAS41008
Indication: Psoriasis

  • Almirall
  • Dimethyl fumarate


Name: Serlopitant (VPD-737)
Indication: Psoriasis

  • Menlo Therapeutics Inc.
  • Neurokinin-1 Receptor Antagonists

Name: Upadacitinib (ABT-494)
Indication: PsA

  • Abbvie
  • JAK inhibitor

Topicals

Name: M518101
Indication: Psoriasis

  • Maruho Co. Ltd.


Name: MC2-01 Cream
Indication: Psoriasis

  • MC2 Therapeutics
  • Calcipotriene and betamethasone dipropionate


Name: Tapinarof (DVMT-505)
Indication: Psoriasis

  • Dermavant Sciences, Inc
  • AhR agonist

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.